State pharmaceutical assistance programs (SPAPs) are likely to see savings generated by the prescription drug reforms included in the Inflation Reduction Act (IRA) of 2022. SPAPs, which help pay prescription drug-related costs for certain populations with limited financial resources, could benefit from expanded low-income subsidy eligibility, Medicare price negotiation, and the Medicare Part D premium cap. An AARP Public Policy Institute report outlines how these reforms will lower costs for the 13 SPAPs currently serving older adults, allowing them to further invest in the health of older residents, and suggests how other states can
revisit SPAPs.
| 
